Pharmacological treatment of Tourette syndrome

Journal of Obsessive-Compulsive and Related Disorders

Volumn 3, Issue 4, 2014, Pages 407-414

  Gilbert, Donald L ^a   Jankovic, Joseph ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Attention deficit; Hyperactivity; Obsessive compulsive; Tics; Tourette

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ARIPIPRAZOLE; ATOMOXETINE; BACLOFEN; CLONAZEPAM; CLONIDINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ETIRACETAM; FLUPHENAZINE; GUANFACINE; HALOPERIDOL; METHYLPHENIDATE; METOCLOPRAMIDE; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; ONDANSETRON; PIMOZIDE; PRAMIPEXOLE; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TOPIRAMATE; ZIPRASIDONE;

ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; COGNITIVE THERAPY; COMORBIDITY; COOPERATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GILLES DE LA TOURETTE SYNDROME; HUMAN; OBSESSIVE COMPULSIVE DISORDER; PATIENT CARE; SYMPTOM; TIC; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84909583199     PISSN: 22113649     EISSN: 22113657     Source Type: Journal    
DOI: 10.1016/j.jocrd.2014.04.006     Document Type: Article

References (125)

1. Allen A.J., Kurlan R.M., Gilbert D.L., et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005, 65:1941-1949.
2. Allen A. J., Spencer T. J., Dunn D. W., Gilbert D. L., Milton D. R., Feldman P. D. (2006). Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome (p. A366-A366), vol. 2006.
3. Anca M.H., Giladi N., Korczyn A.D. Ropinirole in Gilles de la Tourette syndrome. Neurology 2004, 62:1626-1627.
4. Awaad Y., Michon A.M., Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Movement Disorder 2005, 20:714-718.
5. Bernard B.A., Stebbins G.T., Siegel S., et al. Determinants of quality of life in children with Gilles de la Tourette syndrome. Movement Disorder 2009, 24:1070-1073.
6. Bloch M.H., Leckman J.F. Clinical course of Tourette syndrome. Journal of Psychosomatic Research 2009, 67:497-501.
7. Bloch M.H., Panza K.E., Landeros-Weisenberger A., Leckman J.F. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48:884-893.
8. Bloch M.H., Peterson B.S., Scahill L., et al. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with tourette syndrome. Archives of Pediatrics and Adolescent Medicine 2006, 160:65-69.
9. Bonelli R.M., Wenning G.K., Kapfhammer H.P. Huntington[U+05F3]s disease: Present treatments and future therapeutic modalities. International Clinical Psychopharmacology 2004, 19:51-62.
10. Brodie M.J., Chadwick D.W., Anhut H., et al. Gabapentin versus lamotrigine monotherapy: A double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002, 43:993-1000.
11. Bruggeman R., van dL, Buitelaar J.K., Gericke G.S., Hawkridge S.M., Temlett J.A. Risperidone versus pimozide in Tourette[U+05F3]s disorder: A comparative double-blind parallel-group study. Journal of Clinical Psychiatry 2001, 62:50-56.
12. Budman C., Coffey B.J., Shechter R., et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. Journal of Child Adolescent Psychopharmacology 2008, 18:509-515.
13. Canitano R., Vivanti G. Tics and Tourette syndrome in autism spectrum disorders. Autism 2007, 11:19-28.
14. Carter A.S., O'Donnell D.A., Schultz R.T., Scahill L., Leckman J.F., Pauls D.L. Social and emotional adjustment in children affected with Gilles de la Tourette's syndrome: Associations with ADHD and family functioning. Attention Deficit Hyperactivity Disorder. Journal of Child Psychology and Psychiatry 2000, 41:215-223.
15. Castellanos F.X., Giedd J.N., Elia J., et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: Effects of stimulant and dose. Journal of American Academy of Child and Adolescent Psychiatry 1997, 36:589-596.
16. Cavanna A.E., Luoni C., Selvini C., et al. Parent and self-report health-related quality of life measures in young patients with Tourette syndrome. Journal of Child Neurology 2013, 28:1305-1308.
17. Chae J.H., Nahas Z., Wassermann E., et al. A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette[U+05F3]s syndrome. Cognitive and Behavioral Neurology 2004, 17:109-117.
18. Cheung M.Y., Shahed J., Jankovic J. Malignant Tourette syndrome. Movement Disorder 2007, 22:1743-1750.
19. Comings D.E. Tourette syndrome: A hereditary neuropsychiatric spectrum disorder. Annals of Clinical Psychiatry 1994, 6:235-247.
20. Comings D.E., Comings B.G. A controlled family history study of Tourette[U+05F3]s syndrome, II: Alcoholism, drug abuse, and obesity. Journal of Clinical Psychiatry 1990, 51:281-287.
21. Comings D.E., Comings B.G. Clinical and genetic relationships between autism-pervasive developmental disorder and Tourette syndrome: A study of 19 cases. American Journal of Medical Genetics 1991, 39:180-191.
22. Conners C.K., Sitarenios G., Parker J.D., Epstein J.N. The revised Conners[U+05F3] Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. Journal of Abnormal Child Psychology 1998, 26:257-268.
23. Correll C.U., Kane J.M. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: A systematic review. Journal of Child and Adolescent Psychopharmacology 2007, 17:647-656.
24. Cubo E., Gonzalez M., Singer H., et al. Impact of placebo assignment in clinical trials of tic disorders. Movement Disorder 2013, 28:1288-1292.
25. Curtis A., Clarke C.E., Rickards H.E. Cannabinoids for Tourette[U+05F3]s syndrome. Cochrane Database of Systematic Reviews 2009, CD006565.
26. Denckla M.B., Bemporad J.R., MacKay M.C. Tics following methylphenidate administration. A report of 20 cases. Journal of the American Medical Association 1976, 235:1349-1351.
27. Dobbs M., Berger J.R. Cervical myelopathy secondary to violent tics of Tourette[U+05F3]s syndrome. Neurology 2003, 60:1862-1863.
28. Dooley J.M., Gordon K.E., Wood E.P., Camfield C.S., Camfield P.R. The utility of the physical examination and investigations in the pediatric neurology consultation. Pediatric Neurology 2003, 28:96-99.
29. Du Y.S., Li H.F., Vance A., et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Australian and New Zealand Journal of Psychiatry 2008, 42:807-813.
30. DuPaul G.J., Power T.J., Anastopoulos A.D., Reid R. ADHD Rating Scale-IV: Checklist, Norms, and Clinical Interpretations 1998, Guilford Press, New York.
31. Franks R.P. Psychiatric issues of childhood seizure disorders. Child & Adolescent Psychiatric Clinics of North America 2003, 12:551-565.
32. Freeman R.D. Tic disorders and ADHD: Answers from a world-wide clinical dataset on Tourette syndrome. European Child and Adolescent Psychiatry 2007, 16(Suppl. 1):S15-S23.
33. Gadow K.D., Nolan E.E., Sverd J., Sprafkin J., Schneider J. Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. Journal of Child Neurology 2008, 23:981-990.
34. Garcia A.M., Sapyta J.J., Moore P.S., et al. Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). Journal of the American Academy of Child and Adolescent Psychiatry 2010, 49:1024-1033.
35. Gilbert D.L. Treatment of children and adolescents with tics and tourette syndrome. Journal of Child Neurology 2006, 21:690-700.
36. Gilbert D.L., Batterson J.R., Sethuraman G., Sallee F.R. Tic reduction with risperidone vs. pimozide in a randomized, double-blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43:206-214.
37. Gilbert D.L., Budman C.L., Singer H.S., Kurlan R., Chipkin R.E. A D1 receptor antagonist, Ecopipam, for treatment of tics in Tourette syndrome. Clinical Neuropharmacology 2014, 37:26-30.
38. Gilbert D.L., Buncher C.R. Assessment of scientific and ethical issues in two randomized clinical trial designs for patients with Tourette[U+05F3]s syndrome: A model for studies of multiple neuropsychiatric diagnoses. Journal of Neuropsychiatry and Clinical Neurosciences 2005, 17:324-332.
39. Gilbert D.L., Dure L., Sethuraman G., Raab D., Lane J., Sallee F.R. Tic reduction with pergolide in a randomized controlled trial in children. Neurology 2003, 60:606-611.
40. Grados M.A., Mathews C.A. Latent class analysis of gilles de la tourette syndrome using comorbidities: Clinical and genetic implications. Biological Psychiatry 2008, 64:219-225.
41. Hedderick E.F., Morris C.M., Singer H.S. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatric Neurology 2009, 40:420-425.
42. Hesdorffer D.C., Ludvigsson P., Olafsson E., Gudmundsson G., Kjartansson O., Hauser W.A. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Archives of General Psychiatry 2004, 61:731-736.
43. Jankovic J. Tourette[U+05F3]s syndrome. New England Journal of Medicine 2001, 345:1184-1192.
44. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurology 2009, 8:844-856.
45. Jankovic J., Jimenez-Shahed J., Brown L. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Journal of Neurology, Neurosurgery and Psychiatry 2010, 81:70-73.
46. Jankovic J., Kurlan R. Tourette syndrome: evolving concepts. Movement Disorder 2011, 26:1149-1156.
47. Jankovic J., Kurlan R. Tourette syndrome: Evolving concepts. Movement Disorder 2011, 26(6):1149-5677.
48. Jeon S., Walkup J.T., Woods D.W., et al. Detecting a clinically meaningful change in tic severity in Tourette syndrome: A comparison of three methods. Contemporary Clinical Trials 2013, 36:414-420.
49. Jimenez-Shahed J., Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington[U+05F3]s disease and other potential indications. Expert Opinion on Orphan Drugs 2013, 1:423-436.
50. Jucaite A., Takano A., Boström E., et al. AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. The International Journal of Neuropsychopharmacology 2012, 1-9.
51. Kenney C., Hunter C., Davidson A., Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. Journal of Clinical Pharmacology 2008, 48:379-384.
52. Kenney C., Hunter C., Mejia N., Jankovic J. Tetrabenazine in the treatment of Tourette Syndrome. Journal of Pediatric Neurology 2007, 2007:9-13.
53. Klaassen T., Verhey F.R., Sneijders G.H., Rozendaal N., de Vet H.C., van Praag H.M. Treatment of depression in Parkinson[U+05F3]s disease: A meta-analysis. Journal of Neuropsychiatry & Clinical Neurosciences 1995, 7:281-286.
54. Kompoliti K., Goetz C.G. Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Movement Disorder 1998, 13:477-480.
55. Kompoliti K., Goetz C.G., Morrissey M., Leurgans S. Gilles de la Tourette syndrome: Patient[U+05F3]s knowledge and concern of adverse effects. Movement Disorder 2006, 21:248-252.
56. Krauss J.K., Jankovic J. Severe motor tics causing cervical myelopathy in Tourette[U+05F3]s syndrome. Movement Disorder 1996, 11:563-566.
57. Kurlan R. Hypothesis II: Tourette[U+05F3]s syndrome is part of a clinical spectrum that includes normal brain development. Archives of Neurology 1994, 51:1145-1150.
58. Kurlan R. Clinical practice. Tourette[U+05F3]s syndrome. New England Journal of Medicine 2010, 363:2332-2338.
59. Kurlan R., Como P.G., Miller B., et al. The behavioral spectrum of tic disorders: A community-based study. Neurology 2002, 59:414-420.
60. Kurlan R., Crespi G., Coffey B., Mueller-Vahl K., Koval S., Wunderlich G. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette[U+05F3]s syndrome. Movement Disorder 2012, 27:775-778.
61. Kurlan R., Whitmore D., Irvine C., McDermott M.P., Como P.G. Tourette[U+05F3]s syndrome in a special education population: A pilot study involving a single school district. Neurology 1994, 44:699-702.
62. Kwak C., Dat Vuong K., Jankovic J. Premonitory sensory phenomenon in Tourette[U+05F3]s syndrome. Movement Disorder 2003, 18:1530-1533.
63. Kwak C.H., Hanna P.A., Jankovic J. Botulinum toxin in the treatment of tics. Archives of Neurology 2000, 57:1190-1193.
64. Kwon H.J., Lim W.S., Lim M.H., et al. 1-Hz low frequency repetitive transcranial magnetic stimulation in children with Tourette[U+05F3]s syndrome. Neuroscience Letters 2011, 492:1-4.
65. Lawson-Yuen A., Saldivar J.S., Sommer S., Picker J. Familial deletion within NLGN4 associated with autism and Tourette syndrome. European Journal of Human Genetics 2008, 16:614-618.
66. Leckman J.F., Hardin M.T., Riddle M.A., Stevenson J., Ort S.I., Cohen D.J. Clonidine treatment of Gilles de la Tourette[U+05F3]s syndrome. Archives of General Psychiatry 1991, 48:324-328.
67. Leckman J.F., Riddle M.A., Hardin M.T., et al. The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. Journal of the American Academy of Child and Adolescent Psychiatry 1989, 28:566-573.
68. Leckman J.F., Zhang H., Vitale A., et al. Course of tic severity in Tourette syndrome: The first two decades. Pediatrics 1998, 102:14-19.
69. Lewis D., Winner P., Saper J., et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12-17 years of age. Pediatrics 2009, 123:924-934.
70. Lin J.J., Wang H.S., Wong M.C., Wu C.T., Lin K.L. Tourette[U+05F3]s syndrome with cervical disc herniation. Brain & Development 2007, 29:61-63.
71. Marras C., Andrews D., Sime E., Lang A.E. Botulinum toxin for simple motor tics: A randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605-610.
72. McNaught K.S., Mink J.W. Advances in understanding and treatment of Tourette syndrome. Nature Reviews Neurology 2011, 7:667-676.
73. Mindham R.H., Marsden C.D., Parkes J.D. Psychiatric symptoms during l-dopa therapy for Parkinson[U+05F3]s disease and their relationship to physical disability. Psychological Medicine 1976, 6:23-33.
74. Mink J.W., Walkup J.T., Frey K.A., et al. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Movement Disorder 2006, 21:1831-1838.
75. Molina B.S., Flory K., Hinshaw S.P., et al. Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. Journal of the American Academy of Child & Adolescent Psychiatry 2007, 46:1028-1040.
76. Molina B.S., Hinshaw S.P., Swanson J.M., et al. The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48:484-500.
77. Multimodal Treatment of ADHD Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry 1999, 56:1073-1086.
78. Muroi A., Matsumura A., Asakawa H., Enomoto T., Iwasaki N., Nose T. Myelopathy caused by tics in an adolescent, associated with T2 signal intensity changes of the spinal cord. Childs Nervous System. 2002, 18:191-194.
79. Nicolson R., Craven-Thuss B., Smith J., McKinlay B.D., Castellanos F.X. A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette[U+05F3]s disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2005, 44:640-646.
80. O'Brien J.T., Erkinjuntti T., Reisberg B., et al. Vascular cognitive impairment. Lancet Neurology 2003, 2:89-98.
81. Okun M.S., Foote K.D., Wu S.S., et al. A trial of scheduled deep brain stimulation for Tourette syndrome. JAMA Neurol. 2013, 70:85-94.
82. Ondo W.G., Jong D., Davis A. Comparison of weight gain in treatments for Tourette syndrome: Tetrabenazine versus neuroleptic drugs. Journal of Child Neurology 2008, 23:435-437.
83. Paleacu D., Giladi N., Moore O., Stern A., Honigman S., Badarny S. Tetrabenazine treatment in movement disorders. Clinical Neuropharmacology 2004, 27:230-233.
84. Palumbo D., Maughan A., Kurlan R. Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome. Archives of Neurology 1997, 54:475-483.
85. Palumbo D.R., Sallee F.R., Pelham W.E., Bukstein O.G., Daviss W.B., McDermott M.P. Clonidine for Attention-Deficit/Hyperactivity Disorder: I. Efficacy and Tolerability Outcomes. Journal of the American Academy of Child and Adolescent Psychiatry 2008, 47:180-188.
86. Pappert E.J., Goetz C.G., Louis E.D., Blasucci L., Leurgans S. Objective assessments of longitudinal outcome in Gilles de la Tourette[U+05F3]s syndrome. Neurology 2003, 61:936-940.
87. Patten S.B., Fridhandler S., Beck C.A., Metz L.M. Depressive symptoms in a treated multiple sclerosis cohort. Multiple Sclerosis 2003, 9:616-620.
88. Patten S.B., Metz L.M. Depression in multiple sclerosis. Psychotherapy & Psychosomatics 1997, 66:286-292.
89. Pena M.S., Yaltho T.C., Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Movement Disorder 2010.
90. Pena M.S., Yaltho T.C., Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Movement Disorder 2011, 26:147-152.
91. Peterson B.S., Leckman J.F. The temporal dynamics of tics in Gilles de la Tourette syndrome. Biological Psychiatry 1998, 44:1337-1348.
92. Peterson B.S., Pine D.S., Cohen P., Brook J.S. Prospective, longitudinal study of tic, obsessive-compulsive, and attention-deficit/hyperactivity disorders in an epidemiological sample. Journal of the American Academy of Child and Adolescent Psychiatry 2001, 40:685-695.
93. Piacentini J., Woods D.W., Scahill L., et al. Behavior therapy for children with Tourette disorder: A randomized controlled trial. Journal of the American Medical Association 2010, 303:1929-1937.
94. Pringsheim T., Marras C. Pimozide for tics in Tourette[U+05F3]s syndrome. Cochrane Database of Systematic Reviews 2009, CD006996.
95. Robertson M.M. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000, 123(Pt 3):425-462.
96. Robinson R.G. Poststroke depression: Prevalence, diagnosis, treatment, and disease progression. Biological Psychiatry 2003, 54:376-387.
97. Rose M.S., Moldofsky H. Comparison of pimozide with haloperidol in Gilles de la Tourette syndrome [letter]. Lancet 1977, 1:103.
98. Sallee F.R., Lyne A., Wigal T., McGough J.J. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 2009, 19:215-226.
99. Sallee F.R., McGough J., Wigal T., Donahue J., Lyne A., Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48:155-165.
100. Sallee F.R., Nesbitt L., Jackson C., Sine L., Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette[U+05F3]s disorder. American Journal of Psychiatry 1997, 154:1057-1062.
101. Scahill L., Chappell P.B., Kim Y.S., et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry 2001, 158:1067-1074.
102. Scahill L., Erenberg G., Berlin C.M., et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3:192-206.
103. Scahill L., Leckman J.F., Schultz R.T., Katsovich L., Peterson B.S. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130-1135.
104. Seo W.S., Sung H.M., Sea H.S., Bai D.S. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. Journal of Child and Adolescent Psychopharmacology 2008, 18:197-205.
105. Silva R.R., Muñoz D.M., Daniel W., Barickman J., Friedhoff A.J. Causes of haloperidol discontinuation in patients with Tourette[U+05F3]s disorder: Management and alternatives. Journal of Clinical Psychiatry 1996, 57:129-135.
106. Singer H.S. Tourette[U+05F3]s syndrome: From behaviour to biology. Lancet Neurology 2005, 4:149-159.
107. Singer H.S., Gammon K., Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: Controversies in treatment. Journal of Pediatric Neurosciences 1985, 12:71-74.
108. Smith-Hicks C.L., Bridges D.D., Paynter N.P., Singer H.S. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Movement Disorder 2007, 22:1764-1770.
109. Snider L.A., Seligman L.D., Ketchen B.R., et al. Tics and problem behaviors in schoolchildren: Prevalence, characterization, and associations. Pediatrics 2002, 110:331-336.
110. Sweet R.D., Bruun R., Shapiro E., Shapiro A.K. Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Archives of General Psychiatry 1974, 31:857-861.
111. Taragano F.E., Allegri R., Vicario A., Bagnatti P., Lyketsos C.G. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression. International Journal of Geriatric Psychiatry 2001, 16:254-260.
112. Termine C., Luoni C., Selvini C., et al. Mother-child agreement on behavioral ratings in tourette syndrome: A controlled study. Journal of Child Neurology 2014, 29:79-83.
113. Termine C., Selvini C., Rossi G., Balottin U. Emerging treatment strategies in Tourette syndrome: What[U+05F3]s in the pipeline?. International Review of Neurobiology 2013, 112:445-480.
114. The Pediatric OCD Treatment Study (POTS) Team Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of the American Medical Association 2004, 292:1969-1976.
115. Tourette Syndrome Study Group Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 2002, 58:527-536.
116. Viswanathan A., Jimenez-Shahed J., Baizabal Carvallo J.F., Jankovic J. Deep brain stimulation for Tourette syndrome: Target selection. Stereotactic and Functional Neurosurgery 2012, 90:213-224.
117. Wijemanne S., Wu L.J., Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Movement Disorder 2013.
118. Wilhelm S., Peterson A.L., Piacentini J., et al. Randomized trial of behavior therapy for adults with Tourette syndrome. Archives of General Psychiatry 2012, 69:795-803.
119. Wolraich M.L., Lambert W., Doffing M.A., Bickman L., Simmons T., Worley K. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. Journal of Pediatric Psychology 2003, 28:559-567.
120. Wonodi I., Reeves G., Carmichael D., et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Movement Disorder 2007, 22:1777-1782.
121. Woods D.W., Piacentini J., Himle M.B., Chang S. Premonitory Urge for Tics Scale (PUTS): Initial psychometric results and examination of the premonitory urge phenomenon in youths with Tic disorders. Journal of Developmental & Behavioral Pediatrics 2005, 26:397-403.
122. Wu S.W., Harris E., Gilbert D.L. Tic suppression: The medical model. Journal of Child and Adolescent Psychopharmacology 2010, 20:263-276.
123. Wu S.W., Maloney T., Gilbert D.L., et al. Functional MRI-navigated repetitive transcranial magnetic stimulation over supplementary motor area in chronic tic disorders. Brain Stimulation 2014, 7:212-218.
124. Yoo H.K., Joung Y.S., Lee J.S., et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette[U+05F3]s disorder. Journal of Clinical Psychiatry 2013, 74:e772-780.
125. Zinner S.H. Tourette syndrome: Much more than tics. Contemporary Pediatrics 2004, 21:22-49.